

Claims Listing

Claims 1-18. (Cancelled)

19. (Currently amended) A method for treating delaying or reversing the progression of Alzheimer's disease comprising administering a supramolecular antigenic ~~constructs~~ construct reconstituted in a liposome, wherein the supramolecular antigenic ~~constructs~~ construct comprises an amyloid antigenic peptide having the amino acid sequence of β-amyloid or an active fragment thereof, and wherein the antigenic peptide or active fragment thereof is modified with hydrophobic moieties to enhance antigenicity.

20. (original) The method of claim 19, wherein the antigenic peptide or active fragment thereof is modified by pegylation, palmitic acid, poly-amino acids, poly-glycine, poly-histidine, poly-saccharides, polygalacturonic acid, polylactic acid, polyglycolide, chitin, chitosan, synthetic polymers, polyamides, polyurethanes, polyesters, co-polymers or poly(methacrylic acid) and N-(2-hydroxy)propyl methacrylamide.

21. (Withdrawn, previously presented) The method of claim 19, wherein the antigenic peptide or active fragment thereof is modified through pegylation using polyethylene glycol or modified polyethylene glycol.

22. (Withdrawn, previously presented) The method of claim 19, wherein the supramolecular antigenic constructs comprises: a peptide sequence, covalently attached to pegylated lysine--one at each terminus; wherein the free PEG terminus is covalently attached to a molecule of phosphatidylethanolamine.

23. (Previously presented) The method of claim 19, wherein the supramolecular antigenic construct is reconstituted in liposomes consisting of phospholipids and cholesterol.

24. (Previously presented) The method of claim 19, wherein the antigenic peptide

FIRST RESPONSE TO OFFICE ACTION
U.S.S.N. 10/590,073

comprises an amyloid peptide.

25. (Previously presented) The method of claim 19, wherein the amyloid peptide comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.

26. (Previously presented) The method of claim 19, further comprising a pharmaceutical carrier.

27. (Previously presented) The method of claim 19, wherein the supramolecular antigenic constructs may be used to treat disorders comprising Alzheimer's disease, multidrug resistance in cancer cells, or prion diseases.